Carregant...
Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature
INTRODUCTION: Pimavanserin (Nuplazid™) is an atypical antipsychotic currently indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis. The antipsychotic effects of this new agent are believed to occur via selective inverse agonist activity at serotonin...
Guardat en:
| Publicat a: | Ment Health Clin |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
College of Psychiatric & Neurologic Pharmacists
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6007714/ https://ncbi.nlm.nih.gov/pubmed/29955528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.9740/mhc.2017.09.230 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|